Intrinsic Medicine, Inc. is a preclinical-stage therapeutics company. The Company's initial drug candidates are based on bioactive oligosaccharides naturally produced in human milk, or Human Milk Oligosaccharides (HMOs) which directly modulate the immune system and other human cells as well as the gut microbiome. The Company's Oligosaccharide Medicines (OMs) are synthetic biology-produced drugs equivalent to HMOs. The Company's pipeline consists of human-identical milk oligosaccharide (HiMO) drug candidates, including OM001 (HiMO 3’sialyllactose), OM002 (HiMO 2’-fucosyllactose), and OM003 (HiMO 6’-sialyllactose). Its pipeline has the potential to treat gut-brain axis disorders (GBA), and certain inflammatory disorders. The Company's HiMO drug candidates is suitable for convenient oral administration. HiMO drug candidates enable a diverse pipeline of addressable diseases, both within a single HiMO drug candidate and across multiple HiMO drug candidates.